Payment & Shipping Terms:
pharma grade steroids,
pharma group steroids
Injectable Anastrozole Arimidex Steroid 120511-73-1for Anti-Estrogen Breast Cancer Steroid
CAS No: 120511-73-1
Appearance: white powder.
Other drugs in same class:Anastrozole,Letrozole,Tamoxifen citrate,Exemestane
Usage: An aromatase inhibitor. Used as an antineoplastic raw materials.
Potent selective triazole aromatase inhibitors, can inhibit the cytochrome P-450 aromatase enzyme which depends blocking the biosynthesis of estrogen, and estrogen to stimulate breast cancer cell growth factors. Treatment of breast cancer, especially for those with hormone relapse after adjuvant therapy after menopause for women with advanced breast cancer
1). Arimidex (anastrozole) is the aromatase inhibitor of choice. Arimidex’s mechanism of action — blocking conversion of aromatizable steroids to estrogen — is in contrast to the mechanism of action of anti-estrogens such as clomiphene (Clomid) or tamoxifen (Nolvadex), which block estrogen receptors in some tissues, and activate estrogen receptors in others.
1). Anastrozole is prescribed for hormone receptor-positive, early breast cancer in postmenopausal women as adjuvant treatment ( treatment following surgery with or without radiation ). Anastrozole is prescribed as a first-line treatment for hormone receptor-positive or hormone receptor unknown, locally advanced or metastatic breast cancer in postmenopausal women. Anastrozole is also prescribed for the treatment of advanced breast cancer in postmenopausal women with disease progression following treatment with tamoxifen (Nolvadex, Soltamox).
2). ARIMIDEX is approved for adjuvant treatment (treatment following surgery with or without radiation) of postmenopausal women with hormone receptor-positive early breast cancer.
ARIMIDEX is approved for the initial treatment of postmenopausal women with hormone receptor-positive or hormone receptor-unknown locally advanced or metastatic breast cancer and for the treatment of postmenopausal women with advanced breast cancer that has progressed following treatment with tamoxifen. Patients with hormone receptor-negative disease and patients who did not previously respond to tamoxifen therapy rarely responded to ARIMIDEX.
|CAS register number||120511-73-1|
|Appearance||White crystalline powder|
|Package||1kg/aluminium foil bag or as required|
|Usage||can be used as pharmaceutical material|
|Minimum order quantity||10g|
|Shipping||By express courier|
|Shipping leading time||Within 12 hours after receiving the payment|
|Payment options||, MoneyGram, T/T|
Competitive advantages :